Michelle T. Long, MD, MSc
Assistant Professor
Boston Medical Center
Dept of Medicine

MD, Tufts University School of Medicine

Pronouns: she/her/hers

Michelle T. Long, MD, MSc is a physician-scientist with an expertise in Nonalcoholic fatty liver disease (NAFLD), and Assistant Professor of Medicine at Boston University. She completed her clinical training at Massachusetts General Hospital and Boston Medical Center. Dr. Long is the Director of the NAFLD Research Center and the Director of Clinical Research for the Section of Gastroenterology and Hepatology. Her clinical and research interests center on the relationship between NAFLD and cardiovascular disease. Dr. Long is primarily interested in patient-oriented research investigating fibrosis and inflammation in patients with NAFLD and in imaging and risk stratification strategies for hepatic fibrosis. Dr. Long has projects at Boston Medical Center and at the Framingham Heart Study where she is the PI of a study evaluating the prevalence and risk factors for liver fat (steatosis) and fibrosis. In Framingham, she is investigating the clinical and genetic correlates of hepatic steatosis and fibrosis as measured by transient elastography. Dr. Long receives research funding from the NIH (NIDDK), Doris Duke Charitable Foundation, Gilead Sciences, Echosens Corporation, and Boston University. She has expertise in epidemiology, visceral fat, liver imaging including computed tomography, ultrasound, and transient elastography. Dr. Long is also a clinical hepatologist and endoscopist.

Dr. Long is additionally interested in novel therapeutics for NAFLD and Non-alcoholic steatohepatitis (NASH) and runs the clinical trials program for the NAFLD Research Center.

Her other research interests include alcohol-related liver disease, hepatitis C, outcomes in end-stage liver disease/cirrhosis.

Framingham Heart Study

Boston University
Evans Center for Interdisciplinary Biomedical Research

Full Member
Boston University Medical Center
Boston Nutrition Obesity Research Center

2020 Boston University School of Medicine: Resident Research Mentor Award
2019 NASH TAG Conference: Emerging Leader in NAFLD
2016 Boston University School of Medicine: Women's Leadership Conference Selected Participant
2016 Boston University School of Medicine: Faculty Development and Diversity Grant Recipient
2015-2020 Boston University School of Medicine: NIH Loan Repayment Program Recipient
2014 Boston University School of Medicine: 3rd Place, Evans Research Day
2009 Tufts University School of Medicine: Massachusetts Medical Society Scholars Award
2009 Tufts University School of Medicine: Glasgow-Rubin Citation for Academic Achievement
2009 Tufts University School of Medicine: Phi Delta Epsilon Fraternity Award
2009 Tufts University School of Medicine: Alpha Omega Alpha
2008 Tufts University School of Medicine: Magna cum laude Scientific electronic exhibit award
2008 Tufts University School of Medicine: Ada Draper, MD Scholarship
2006-2007 Tufts University School of Medicine: Boston Albert Schweitzer Fellowship
2006-2008 Tufts University School of Medicine: USA Funds Scholarship
2004 Middlebury College: Magna cum laude

Resting metabolic signature of non-alcoholic fatty liver disease and the metabolic response to acute exercise in a community based sample
07/01/2019 - 06/30/2022 (PI)
Doris Duke Charitable Foundation

Prevalence and risk factors for hepatic steatosis and fibrosis as measured by transient elastography
03/15/2016 - 05/31/2019 (PI)

Identifying clinical and genetic correlates of hepatic fibrosis from fatty liver disease in the…
01/12/2018 - 11/30/2022 (PI)

AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
07/01/2019 - 07/31/2022 (PI)
Allergan Sales, LLC

12/06/2018 - 12/06/2021 (PI)

12/06/2018 - 12/06/2021 (PI)

Determining the burden, heritability, and clinical implications of increased liver stiffness from…
01/02/2019 - 01/01/2021 (PI)
Gilead Sciences

A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating …
05/16/2017 - 05/16/2020 (PI)
Intercept Pharmaceuticals, Inc.

A Double-Blind, Placebo-Controlled Trial of Obeticholic Acid in Patients with moderately severe A…
10/06/2016 - 10/05/2018 (PI)
Indiana University NIH-NIAAA


Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Zhang X, Xu H, Li GHY, Long MT, Cheung CL, Vasan RS, Hsu YH, Kiel DP, Liu CT. Metabolomics insights into osteoporosis through association with bone mineral density. J Bone Miner Res. 2021 Jan 12.View Related Profiles. PMID: 33434288
  2. Mohanty A, Eshein A, Kamineni P, Avissar U, Bliss CM, Long MT, Lowe RC, Moore TC, Nunes DP, Backman V, Roy HK. Quantification of gastric mucosal microcirculation as a surrogate marker of portal hypertension by spatially resolved subdiffuse reflectance spectroscopy in diagnosis of cirrhosis: a proof of concept study. Gastrointest Endosc. 2020 Dec 29.View Related Profiles. PMID: 33385462
  3. Long MT, Zhang X, Xu H, Liu CT, Corey KE, Chung RT, Loomba R, Benjamin EJ. Hepatic fibrosis associates with multiple cardiometabolic disease risk factors: The Framingham Heart Study. Hepatology. 2020 Oct 30.View Related Profiles. PMID: 33125745
  4. DeCoste LR, Wang N, Palmisano JN, Mendez J, Hoffmann U, Benjamin EJ, Long MT. Adherence to Ideal Cardiovascular Health Metrics Is Associated With Reduced Odds of Hepatic Steatosis. Hepatol Commun. 2021 Jan; 5(1):74-82.View Related Profiles. PMID: 33437902
  5. Long MT, Naimi TS. Reply. Clin Gastroenterol Hepatol. 2020 Sep 23.View Related Profiles. PMID: 33248106
  6. Bianco C, Romeo S, Petta S, Long MT, Valenti L. MAFLD vs NAFLD: Let the contest begin! Liver Int. 2020 09; 40(9):2079-2081. PMID: 32930521
  7. Chiu LS, Pedley A, Massaro JM, Benjamin EJ, Mitchell GF, McManus DD, Aragam J, Vasan RS, Cheng S, Long MT. The association of non-alcoholic fatty liver disease and cardiac structure and function-Framingham Heart Study. Liver Int. 2020 10; 40(10):2445-2454.View Related Profiles. PMID: 32654390
  8. Long MT, Gandhi S, Loomba R. Advances in non-invasive biomarkers for the diagnosis and monitoring of non-alcoholic fatty liver disease. Metabolism. 2020 10; 111S:154259. PMID: 32387227
  9. Brunner KT, Pedley A, Massaro JM, Hoffmann U, Benjamin EJ, Long MT. Increasing liver fat is associated with progression of cardiovascular risk factors. Liver Int. 2020 06; 40(6):1339-1343.View Related Profiles. PMID: 32301571
  10. Fricker ZP, Mukthinuthalapati VVPK, Akinyeye S, Chalasani N, Attar BM, Balakrishnan M, Ghabril M, Long MT. MELD-Na Is More Strongly Associated with Risk of Infection and Outcomes Than Other Characteristics of Patients with Cirrhosis. Dig Dis Sci. 2021 Jan; 66(1):247-256.View Related Profiles. PMID: 32100160
Showing 10 of 53 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 53 publications over 8 distinct years, with a maximum of 13 publications in 2019


Dr. Long mentors Fellows, PhD Candidates, Residents, Medical Students and Undergraduate Students.

Available to Mentor as: (Review Mentor Role Definitions):
  • Advisor
  • Career Mentor
  • Co-Mentor or Peer Mentor
  • Diversity Mentor
  • Education Mentor
  • Project Mentor
  • Research / Scholarly Mentor
  • Work / Life Integration Mentor
Contact for Mentoring:
  • Email (see 'Contact Info')

818 Harrison Ave
Boston MA 02118
Google Map

Long's Networks
Click the "See All" links for more information and interactive visualizations
Media Mentions
Similar People
Same Department